Bis(4-aminobutan-2-yloxy)-oxoazanium

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: Bis(4-aminobutan-2-yloxy)-oxoazanium
• 英文别名: bis(4-aminobutan-2-yloxy)-oxoazanium
• 化学式: C8H20N3O3+
• 分子量: 206.26
• InChiKey: ZVYHALHKDJODPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• EXTENDED RELEASE COMPOSITIONS OF AN AMINO-C2-C6-ALKYL NITRATE
  申请人：Cardiolynx AG

  公开号：EP2887927B1

  公开（公告）日：2018-03-28
• EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE
  申请人：Cardiolynx AG

  公开号：EP2887927A1

  公开（公告）日：2015-07-01
• NO DONORS FOR THE TREATMENT OF IMPAIRED TISSUE PERFUSION
  申请人：MIRANDAPHARMACEUTICALS AG

  公开号：US20180036259A1

  公开（公告）日：2018-02-08

  A method for treatment of prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion, comprising administering an amino-C 2 -C 6 -alkyl nitrate, an amino-C 2 -C 4 -alkyl nitrate, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. The disease or condition is a micro- and/or macro-vascular disease selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue. Examples of such diseases are diseases associated with impaired wound healing (including burning injuries), ulcers (e.g. diabetic foot ulcer), and specifically severe peripheral artery disease including critical limb ischaemia in patients with or without type 2 diabetes, Moyamoya disease or metabolic disorders leading to vascular dysfunction.
• [EN] EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE<br/>[FR] COMPOSITIONS DE NITRATE D'AMINOALKYLE À DIFFUSION PROLONGÉE
  申请人：CARDIOLYNX AG

  公开号：WO2014029841A1

  公开（公告）日：2014-02-27

  The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.
• [EN] NO DONORS FOR THE TREATMENT OF IMPAIRED TISSUE PERFUSION<br/>[FR] DONNEURS DE NO POUR LE TRAITEMENT D'UNE PERFUSION TISSULAIRE ALTÉRÉE
  申请人：CARDIOLYNX AG

  公开号：WO2016135262A1

  公开（公告）日：2016-09-01

  The invention relates to the field of medicine and particularly to the use of amino-C2-C6-alkyl nitrates or amino-C2-C4-alkyl nitrates or the pharmaceutically acceptable salt thereof for the treatment and prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion. More particularly the invention provides novel treatment options for micro- and/or macro-vascular diseases selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue. Examples of such diseases are diseases associated with impaired wound healing (including burning injuries), ulcers (e.g. diabetic foot ulcer), and specifically severe peripheral artery disease including critical limb ischaemia in patients with or without type 2 diabetes, Moyamoya disease or metabolic disorders leading to vascular dysfunction. The invention also relates to the use of said amino-alkyl nitrates and the pharmaceutically acceptable salt thereof in the form of an extended release composition or in the form of skin patches. The most preferred amino-alkyl nitrate in accordance with the invention is 2-aminoethyl nitrate or its tosylate salt.